Company Update A p r i l
|
|
- Juniper Alexander
- 5 years ago
- Views:
Transcription
1 Company Update April 2017
2 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of We caution investors that forward-looking statements are based on management s expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, those associated with: the potential market opportunity and net sales for SUSTOL, HTX-019 and HTX-011, whether the HTX-011 Phase 2 study results are indicative of the results in future studies, the sufficiency of the Phase 2 data to allow the commencement of Phase 3 registration studies for HTX-011, the timing of acceptance of the NDA for HTX-019, the timing of the NDA filing for HTX-011, the timing of initiating Phase 3 studies for HTX-011, the projected sufficiency of our capital position for future periods, our ability to repay any indebtedness, the progress in the research and development of HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and we take no obligation to update or revise these statements except as may be required by law. 2
3 Status of Product Portfolio CINV Pain Preclinical Clinical NDA Approved SUSTOL (granisetron) extendedrelease injection Now Approved by U.S. Food and Drug Administration CINVANTI (HTX- 019) aprepitant for injection IV NK 1 for CINV Prevention NDA submitted January 2017 HTX-011 bupivacaine + meloxicam ER Local Administration Post-Op Pain in Local Administration Data from four positive Phase 2 studies in multiple surgical models HTX-011 bupivacaine + meloxicam ER Nerve Block Post-Op Pain in Nerve Block Phase 2 program in nerve block initiated 3
4 CINV PROGRAMS: SUSTOL CINVANTI (aprepitant for injection)
5 SUSTOL Performance Date of first commercial sale: October 11, practices have begun trial and evaluation of SUSTOL representing ~20% of the 1.4M targeted Aloxi units Launch Update Q4 performance: ~3,200 units sold, $495 WAC, ~$1.3M net sales Positive payer coverage: all 12 Medicare MACs covering (44M lives) and commercial plans representing 139M Market Research Insights (Conducted eight weeks post-launch) Practices go through a buying process to evaluate adoption of new drugs which may last several quarters Practices assess coverage, time to payment, reimbursement rate in addition to clinical experience and impact to practice operations HCPs who have begun SUSTOL trial, report positive experiences both clinically and operationally Most RNs with SUSTOL experience are satisfied and have been able to administer it successfully 5
6 46 Percent of MDs Evaluating SUSTOL as Potential Branded Agent of Choice (~6-9 Month Timeline) Degree of MD Experience With SUSTOL Practice s Experience With SUSTOL Trial Timing for SUSTOL To Be Brand of Choice 100% 17% I and other MDs in my practice have used SUSTOL Efficacy 8% 38% 31% 100% 6% 1-3 months 80% 23% I have used SUSTOL but other MDs have not Safety 8% 38% 31% 80% 27% 4-6 months 60% 40% 11% 5% I have not used SUSTOL but other MDs have We will try SUSTOL and are operationalizing it Preparation and administration Payer coverage 8% 8% 31% 46% 15% 23% 60% 40% 13% 10% > 6 months SUSTOL will probably be our brand of choice but not sure when 20% 0% 23% 7% 13% SUSTOL is under consideration We have decided not to use SUSTOL No discussions regarding SUSTOL to date Impact to practice operations Payer reimbursement rate / time 15% 31% 8% 23% 8% 8% Extremely positive (6-7) Positive (5) Negative (3) Extremely Negative (1-2) 20% 0% 39% 5% Not yet sure if SUSTOL will become our brand of choice SUSTOL won t be our brand of choice Which of the following best describes you / your practice? Please select one. - Putnam Physician Survey Nov 2016 (N=85) What has been the experience with SUSTOL use in your practice? Please rate Putnam Practice Manager Survey Nov 2016 (N=40) In what timeframe do you expect SUSTOL to become the practice s branded 5-HT3 of choice? - Putnam Physician Survey Nov 2016 (N=85) 6
7 Most RNs with SUSTOL Experience are Satisfied, Have Administered Successfully RN Overall Experience Administering SUSTOL RN View of SUSTOL vs. other oncology SC products 100% 14% 100% 14% SUSTOL is similar to other subcutaneous injections in oncology 80% 80% 60% 57% Very satisfied (6-7) Satisfied (5) 60% 40% Neither satisfied nor dissatisfied (4) Dissatisfied (3) Very dissatisfied(1-2) 40% 81% SUSTOL prep and admin are unique, but we have been able to administer it successfully 20% 24% 20% 0% 5% 0% 5% We have had significant difficulty administering SUSTOL 7 Please rate your overall experience administering SUSTOL to patients. Please rate Putnam Nurse Survey Nov 2016 (N=85, n=21) Which of the following best describes your experience preparing and administering SUSTOL to patients? - Putnam Nurse Survey Nov 2016 (N=85, n=21)
8 CINV Prophylaxis Requires Two Complimentary Mechanisms of Action EMEND IV is currently the only intravenous NK 1 receptor antagonist on the US market and has >90% of the total NK 1 market Infusion reactions (predominately infusion site pain) and hypersensitivity reactions observed with EMEND IV are believed to be caused by the surfactant polysorbate 80 in the product CINVANTI (HTX-019) (aprepitant for injection) is an investigational proprietary, surfactant-free intravenous formulation of the NK 1 receptor antagonist aprepitant 8
9 CINVANTI (HTX-019) for CINV NDA filed in Jan CINVANTI is a proprietary, surfactant-free intravenous (IV) formulation of the NK 1 receptor antagonist aprepitant Bioequivalency study comparing HTX-019 to EMEND IV (fosaprepitant) completed: Bioequivalence achieved for AUC Significantly fewer adverse events with HTX-019 Direct competitor to the >1 million units of EMEND IV used annually US 15/083,071 received a notice of allowance and will provide exclusivity to March 2036 SAFETY HTX-019 EMEND IV Events Patients Events Patients Total AEs 27 21% 54 28% AEs considered related 18 15% 52 28% SAEs Moderate AEs 0-6 2% AEs leading to discontinuations Final dataset BE Study #104 Safety Results 0-2 2% 100 subjects received HTX-019 and EMEND IV in standard cross-over design Conclusion: HTX-019 was better tolerated than EMEND IV, with 65% fewer AEs at least possibly related to treatment, no AEs of greater than mild severity, no premature discontinuations 9
10 2017 CINV Franchise Outlook Heron expects steady but measured growth in SUSTOL trial and adoption Anticipate $15M - $25M in SUSTOL net sales in 2017 CINVANTI (HTX-019) program advancing NDA submitted January 2017 Anticipate approval Q4 2017, launch Q If approved, Heron would be the first company to address both mechanisms of action for the prophylaxis of CINV with injectable products Offers strong strategic and operational fit with existing commercial organization 10
11 Post-Operative Pain Program HTX-011: Proprietary Extended-Release Combination of Bupivacaine + Meloxicam
12 Number of Procedures (Millions) Market Is Large and Local Anesthetic Use Is Common, but Long-Acting Anesthetics Have Not Fulfilled the Promise Procedures Requiring Post- Operative Pain Relief, Local Anesthetic Usage Across Key Surgeries, * Key Limiters of Current Long- Acting Anesthetics Penetration % Generic local anesthetics 23% No local anesthetics 3% long-acting anesthetics Perceived inability to achieve marketed duration of efficacy 2 No large scale studies have shown superiority versus bupivacaine solution HCPs not persuaded that incremental efficacy is worth the cost Procedure growth driven by aging population and more active seniors Sources: 1- DRG claims analysis (2015), DRG Post-Operative Pain Pharmacor; 2- DRG physician and P&T member interviews (2016; n=106); *Based on analysis of current post-operative pain management across 40 target procedures (~28M procedures) Formulary access restrictions 2 Many institutions restrict usage to certain departments, procedures, or do not have a long-acting local anesthetic on formulary Very low penetration in ASC and office settings 1
13 HTX-011 Has the Potential to Transform Post- Operative Pain Management Product Attribute Generic Local Anesthetics Long-Acting Local Anesthetics HTX-011 Extended-release formulation No Yes Yes Synergistic MOA potentiates local anesthetic efficacy by reducing inflammation No No Yes Consistent 72 hour efficacy No No Yes Head-to-head superiority vs. bupivacaine N/A No Yes Applicable in large and small procedures without admixture with bupivacaine solution Easy to learn, flexible administration with potential safety advantages N/A No Yes No No Yes I would love a product that is superior to Exparel in that it actually provided 72 hours of pain relief; this would reduce rates of nausea, vomiting, and constipation and help us discharge patients sooner. General Surgeon 1 We re looking for an injectable lasting 72 hours; this would address the critical, most painful window of time following surgery and could potentially eliminate the need for additional pain treatments. Plastic Surgeon 1 If a local anesthetic could provide significant pain relief for hours, patients could be up and moving more quickly and have significant reduction in length of stay as well as opioid use post-operatively. Orthopedic Surgeon 1 If we could numb the surgical area for three days, we would have a lot of patient satisfaction and if a patient is satisfied, they re not going to be calling us for the next three days. Anesthesiologist 1 13 Source: 1 DRG physician and P&T member interviews (2016; n=106)
14 ACUTE PAIN AFTER SURGERY IS AN IMPORTANT COMPONENT OF CHRONIC OPIOID ABUSE 14
15 Risk of Chronic Opioid Use After Selected Surgeries Adjusted Odds Ratio for Chronic Opioid Use Total Knee Arthroplasty 5.1 Open Cholecystectomy 3.6 Simple Mastectomy Total Hip Arthroplasty Open Appendectomy Laproscopic Cholecystectomy Cesarean Delivery 1.3 Based on data from 641,941 opioid-naïve surgical patients compared to 18 million opioid-naïve non-surgical patients (Sun, et al. JAMA Internal Med 2016; 176(9): )
16 In Addition to Potential Addiction, Opioids Increase Healthcare Costs Due to a High Rate of Side-Effects Cost of Opioid-Related Adverse Drug Events 1,2 Moderate to Severe Opioid- Induced ADE Cost per ADE Events in 2013 $ Ileus $6,141 Pruritus $502 Urinary Retention $1,867 Respiratory Depression $1,504 PONV $1,225 Mental Status Change $2,263 *All AE costs derived from Oderda 2003 with exception of ileus which is from Simons et al. Calculated from the half-year (January-June) data of the "Inpatient Hospital Services" component of the medical consumer price index in Source: US Bureau of Labor Statistics Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25: Simons R, Kim M, Chow W. Retrospective analyses of adverse events and economic costs [abstract taken from Reg Anesth Pain Med. 2009;PS3:17].
17 Reducing Pain Signals at the Site of the Incision May Decrease the Development of Chronic Pain Activing on opiate receptors in the brain, opioids can reduce the sensation of pain, but do not block transmission of the pain signals. Occasionally, the affected nerves become hyper-stimulated resulting in chronic pain. HTX-011 directly blocks transmission of the pain signal, potentially reducing the chance of chronic pain 17
18 Percentage of Maximal Force (60 gm) Tolerated by Animal Biochronomer Bupivacaine Produced Significant Reductions in Pain in Preclinical Models 1 Pig Post-Operative Pain Model Saline Control Biochronomer Bupivacaine Bupivacaine Liposome Injectable Suspension (2) Higher bar = greater analgesia HOURS Post-operative pain model in pigs from Castle et al, 2013 EPJ 2. Human dose of bupivacaine liposome with 40% smaller incision (n=4 pigs)
19 Inflammation Plays a Key Role in Pain Management (Current local anesthetics do not address this) BUPH + BUPN + H + BUPH + BUPN + H + Outside membrane Inside membrane Nerve Cell Membrane Inflammation produces an acidic environment Shifts the balance to ionized form, which is unable to penetrate nerve cell membrane Acidic environment associated with inflammation results in far less drug penetrating the nerve membrane and reduced anesthetic effects 1,2 Bupivacaine is very sensitive to reduced ph Addition of meloxicam is designed to help reduce local inflammation and allow bupivacaine to work better in the first several days after surgery Ueno, et al. J of Inflammation Research 1: Local anesthetic nerve penetration model adapted from Becker and Reed, Anesth Prog 53:
20 Percentage of Maximal Force (60 gm) Tolerated Unique Combination of Bupivacaine & Meloxicam Produced Complete Analgesia 1 Pig Post-Operative Pain Model Saline Control Bupivacaine Liposome Injectable Suspension (2) Biochronomer Bupivacaine Biochronomer Bupivacaine + Meloxicam 6 Day Release Higher bar = Greater analgesia Post-operative pain model in pigs from Castle et al, 2013 EPJ Hours 2. Human dose of bupivacaine liposome with 40% smaller incision (n=4 pigs in each arm)
21 >72 Hour Duration of Action Seen as Ideal Ideal Duration of Efficacy for Long- Acting Local Anesthetic 5 days 4% 4 days 9% >5 days 2% 24 hours 12% Minimally Acceptable Duration of Efficacy for Long-Acting Local Anesthetic 72 hours 11% 72 hours 46% 48 hours 27% 48 hours 45% 24 hours 44% Source: Decision Resources Post-Operative Pain Physician Research Initiative 2014 (N=30 qualitative interviews; N=184 quantitative survey) 21
22 Percentage of Maximal Force (60 gm) Tolerated HTX-011 s Unique Combination of Bupivacaine & Meloxicam Produced Marked Analgesia Through 72 Hours 1 Pig Post-Operative Pain Model Saline Control Biochronomer Bupivacaine HTX-011 Bupivacaine Liposome Injectable Suspension (2) Biochronomer Meloxicam 22 Higher bar = Greater analgesia Hours Post-operative pain model in pigs from Castle et al, 2013 EPJ 2. Human dose of bupivacaine liposome with 40% smaller incision (n=4 pigs in each arm)
23 Percent of Maximum Force Activity of HTX-011 Cannot Be Replicated By Systemic Administration of Meloxicam Along With ER Bupivacaine Pig Post-Operative Pain Model Saline Placebo HTX-011 (Bupivacaine + Meloxicam) Biochronomer Bupivacaine + Injectable Meloxicam * 70.0 Higher bar = Greater analgesia *Same dose of meloxicam as in HTX-011 administered SQ Post-operative pain model in pigs from Castle et al, 2013 EPJ Hours 23 (n=4 pigs in each arm)
24 HTX-011 Clinical Experience Shows It Has the Potential to Transform Post-Operative Pain Control Previously released HTX-011 clinical data has demonstrated: Unprecedented statistically significant reductions in both pain and opioid use lasting up to 96 hours after surgery Utility in both small procedures (bunion) and medium size procedures (hernia) Ease of use: instillation, which is a faster, easier and potentially safer route of administration was demonstrated to be equally effective to standard injections Future studies will utilize the instillation route of administration, as appropriate Formulation work now complete; only data from the optimized formulation will be presented in the future Data included in this presentation will further confirm the above and provide evidence of even broader utility, including one of the largest incisions, abdominoplasty 24
25 25 HTX-011 STUDY 203: Phase 2 Abdominoplasty
26 Study 203: Abdominoplasty Study Design & Demographics HTX mg Inj HTX mg Inj HTX mg Inj Saline Placebo Injection HTX mg Instillation* Saline Placebo Instillation* HTX mg significantly reduced pain (SPI 0-24 p=0.012); no additional benefit seen with 600mg Data from instillation, the optimal route of administration, presented Characteristic Parameter Saline Placebo HTX mg Age (Years) n Mean Minimum Maximum Gender n (%) Male 0 (0) 0 (0) Female 21 (100) 20 (100) Race n (%) Caucasian 16 (76.2) 15 (75.0) African American 5 (23.8) 5 (25.0) Asian 0 (0) 0 (0) Other 0 (0) 0 (0) Ethnicity n (%) Hispanic 5 (23.8) 7 (35.0) Not Hispanic 16 (76.2) 13 (65.0) 26 *Drug products predominantly instilled with a small number of injections around the plication
27 HTX-011: Instillation Faster, Easier and Potentially Safer Compared to injection, instillation into the incision site is: Easier to administer and less invasive, avoiding up to 50 or more injections into the skin with large operations Safer, reducing the risk of venous puncture 27
28 Mean Pain Index Study 203: Mean Pain Intensity Scores* HTX-011 Is Significantly Better Than Placebo Through 96 Hours After Abdominoplasty SPI 0-24 p=0.086 HTX mg Instillation (n=20) SPI p=0.007 SPI 0-48 p=0.018 Saline Placebo (n=21) SPI p=0.038 SPI 0-72 would likely be the Phase 3 endpoint SPI 0-72 p=0.016 SPI p=0.016 SPI 0-96 p= Results confirm that HTX-011 can be successfully used in even the largest incisions 53 patients an arm should be sufficient to achieve p<0.05 for SPI 0-24 Hours 28 *LOCF method used to account for missing data, no adjustment for use of rescue medications
29 Study 203: HTX-011 Significantly Reduces Opioid Use Mean Opioid Rescue Over Time Placebo (P) (n=21) 0 24 hours 25.9mg 0 48 hours 40.8mg 0 72 hours 51.3mg 0 96 hours 52.9mg HTX mg (n=20) 16.1mg p= mg p= mg p= mg p=0.011 HTX-011 produced significant reductions in opioid rescue medication through 96 hours after abdominoplasty 29
30 Study 203: Treatment-Emergent Related Adverse Reactions for All Cohorts* Preferred Term Saline Placebo (n=84) HTX-011 (n=68) Any Adverse Event 25.0% 25.0% Nausea 7.1% 7.4% Vomiting 1.2% 2.9% Headache 3.6% 7.4% Dizziness 3.6% 0 Hypoesthesia 1.2% 2.9% Wound dehiscence 2.4% 1.5% Pruritus 8.3% 2.9% Hypotension 2.4% 4.4% Decreased appetite 0 2.9% *Adverse events considered at least possibly related with an incidence of >2% 30
31 31 HTX-011 STUDY 208: Phase 2 Bunionectomy
32 Study 208: Bunionectomy Study Design & Demographics HTX mg HTX mg HTX mg Bupivacaine 50mg Saline Placebo HTX mg HTX mg HTX mg on-going Characteristic Parameter Saline Bupivacaine HTX mg HTX mg HTX mg Age (Years) n Mean Minimum Maximum Gender n (%) Male 12 (14.0) 2 (13.3) 5 (16.7)) 11 (19.6) 4 (11.4) Female 74 (86.0) 13 (86.7) 25 (83.3) 45 (80.4) 31 (88.6) Race n (%) Caucasian 50 (58.1) 8 (53.3) 24 (80.0) 38 (67.9) 21(60.0) African American 30 (34.9) 6 (40.0) 4 (13.3) 17 (30.4) 13 (37.1) Other 6 (7.0) 1 (6.7) 2 (6.7) 1 (1.8) 1 (2.9) Ethnicity n (%) Hispanic 21 (24.4) 2 (13.3) 5 (16.7) 18 (32.1) 7 (20.0) Not Hispanic 65 (75.6) 13 (86.7) 25 (83.3) 38 (67.9) 28 (80.0) Open wound and closed wound injections combined 32
33 Mean Pain Intensity Study 208: Mean Pain Intensity Scores* HTX-011 Is Significantly Better Than Placebo For All Doses Tested SPI mg v P: p= mg v P: p= mg v P: p= SPI mg v P: p< mg v P: p< mg v P: p< SPI mg v P: p< mg v P: p< mg v P: p= Hours SPI mg v P: p< mg v P: p= mg v P: p= SPI mg v P: p< mg v P: p= mg v P: p=0.061 SPI 0-72 would likely be the Phase 3 endpoint HTX mg HTX mg HTX mg Bupivacaine 50mg Saline Placebo 33 *LOCF method used to account for missing data, no adjustment for use of rescue medications
34 Mean Pain Intensity Study 208: Mean Pain Intensity Scores* HTX-011 Is Significantly Better Than Bupivacaine For All Doses Tested SPI mg v B: p< mg v B: p= mg v B: p= SPI mg v P: p= mg v P: p= mg v P: p=0.127 SPI mg v B: p< mg v B: p= mg v B: p= Hours SPI mg v B: p= mg v B: p= mg v B: p= SPI mg v B: p= mg v B: p= mg v B: p=0.196 HTX mg HTX mg HTX mg Bupivacaine 50mg Saline Placebo 60mg of bupivacaine combined with meloxicam in HTX-011 is significantly better than 50mg of bupivacaine solution through 48 hours 34 *LOCF method used to account for missing data, no adjustment for use of rescue medications
35 Study 208: HTX-011 Significantly Reduces Opioid Use Mean Opioid Rescue Over Time Placebo (P) (n=86) Bupivacaine Solution (B) (n=15) 0 24 hours 16.5mg 16.3mg 0 48 hours 26.6mg 28.6mg 0 72 hours 33.2mg 35.8mg 0 96 hours 33.8mg 35.8mg HTX mg (n=56) 8.0mg p< v P p= v B 17.8mg p= v P p= v B 23.8mg p= v P p= v B 24.6mg p= v P p= v B HTX mg (n=35) 8.2mg p< v P p=0.002 v B 15.2mg p= v P p= v B 20.5mg p= v P p= v B 20.7mg p=0.005 v P p= v B Doses down to 60mg HTX-011 produced significant reductions in opioid rescue medication and significant increases in median time to first opioid (increased by 300%) and the percent of opioid-free patients through 96 hours (increased by 240%) 35
36 Study 208: Treatment-Emergent Related Adverse Reactions for All Cohorts * Preferred Term Saline Placebo (n=86) Bupivacaine (n=15) HTX-011 (n=121) Any Adverse Event 20.9% 20.0% 27.3% Nausea 9.3% 13.3% 14.0% Vomiting 11.6% 6.7% 3.3% Erythema 1.2% 0 5.0% Headache 1.2% 0 5.8% Swelling % *Adverse events considered at least possibly related with an incidence of >2% 36
37 37 HTX-011 STUDY 202: Phase 2 Hernia Repair Data Presented at 2016 Pain Week
38 Part B HTX-011 Study 202: Herniorrhaphy Study Design HTX mg Injection Instillation HTX mg Saline Injection Instillation Injection 38
39 Instillation and Injection Reduced Pain Equally Well Mean SPI HTX-011B 400mg Injection (N=14) HTX-011B 400mg Instillation (N=16) Saline Placebo (N=31) 39
40 Mean Pain Intensity Study 202: Mean Pain Intensity Scores HTX mg Significantly Better than Placebo Through 48 hours 8 7 SPI p= SPI 0-24 p= SPI 0-48 p=0.025 SPI 0-72 p=0.082 SPI 0-96 p= HTX mg HTX mg Saline Placebo 40 *LOCF method used to account for missing data, no adjustment for use of rescue medications P-values are for the 400 mg dose
41 Study 202: Opioid Use Substantially Reduced Consistent with the significant reductions in pain observed with HTX-011, opiate use was also reduced: Percent of patients who required no opioid rescue medication for the 96 hour study period substantially increased (24.1% versus 6.5%) Mean total opioid consumption decreased by 22.4% through 96 hours post-surgery 41
42 Summary of Treatment-Emergent Adverse Events (TEAEs) in Study 202* Preferred Term HTX-011B 200 mg (N=31) HTX-011B 400 mg (N=30) Saline Placebo (N=31) Any TEAE 12 (38.7%) 10 (33.3%) 16 (51.6%) >1 TEAE in any treatment arm Nausea 2 (6.5%) 5 (16.7%) 4 (12.9%) Headache 3 (9.7%) 3 (10.0%) 0 Constipation 3 (9.7%) 1 (3.3%) 5 (16.1%) Hypersensitivity (6.5%) 42
43 SYNERGY BETWEEN BUPIVACAINE AND MELOXICAM HAS BEEN CONFIRMED IN TWO PAIN CLINICAL MODELS HTX-011 SIGNIFICANTLY BETTER THAN EITHER COMPONENT ALONE 43
44 AUC LSMD vs Placebo HTX-011 Has Demonstrated Significantly Greater Pain Reduction Than Either Bupivacaine or Meloxicam Alone Comparison of AUC 0-72 HTX mg (Bupivacaine) HTX HTX-009 HTX-009 (Meloxicam) HTX mg (Bupivacaine + Meloxicam) 140 ~7-fold Synergy ~9-fold Synergy * * * * p < 0.05 wwocf Bunion Hernia 44
45 Pain Score (Saline minus Exparel) Plasma Bupivacaine (ng/ml) Δ Pain Score (Saline HTX-002) No Extended Release Bupivacaine Has Demonstrated a PK PD Relationship EXPAREL (ER Bupivacaine) No PK-PD Relationship HTX-002 (ER Bupivacaine) No PK-PD Relationship Pain Score Plasma Conc Hours PK PD data from Exparel Bunionectomy Study; Golf, et. al. 45
46 Unique Combination of Bupivacaine & Meloxicam Demonstrates Clear PK PD Relationship For the first time an extended release local anesthetic has shown a clinical PK PD relationship Study 208 Similar PK PD relationship observed with HTX-011 in Study 202 Hernia Repair 46
47 PHASE 2 STUDIES IN TKA AND NERVE BLOCK HAVE STARTED 47
48 Cohort 1 Cohort 2 Study 209: Total Knee Arthroplasty Study Design (n=120) HTX mg Instillation ± Injection HTX mg Instillation ± Injection Saline Placebo Injection Saline Placebo Injection Bupivacaine 150 mg Injection Bupivacaine 150 mg Injection 48
49 Cohort 1 Cohort 2 Study 211: Pectoral Pocket Nerve Block in Breast Augmentation Study Design (n=72) HTX mg Nerve Block HTX to 120 mg Nerve Block Saline Placebo Nerve Block Saline Placebo Nerve Block Bupivacaine 50 mg Nerve Block Bupivacaine 50 mg Nerve Block 49
50 Force in Grams HTX-011 Shows Durable Response in Sciatic Nerve Block Model in Pigs Saline Bupivacaine 25 mg Exparel 106 mg HTX mg H 1H 2H 4H 6H 8H 9H 10H 24H 28H 48H HOURS 50
51 Summary: HTX-011 Is Poised to Fulfill the Promise of Long-Acting Local Anesthetics in Post-Op Pain Large, growing market opportunity Differentiated, synergistic mechanism addresses inflammation a key inhibitor of both generic and long-acting local anesthetics Demonstrated superiority vs. generic bupivacaine solution supports value story Consistent 72-hour efficacy - Pain reduction - Opioid reduction Applicable in large and small procedures without admixture with bupivacaine solution reducing chance of dosing errors and systemic toxicity Flexible administration with potential safety advantages Potential to address most pressing unmet needs cited by key stakeholders patients, surgeons, anesthesiologists & formulary decision makers De-risked Phase 3 development program and extensive patent protection through
52 Key Catalysts in Pain & CINV Franchises HTX-011 for Post-Operative Pain Early Q1 Top-line abdominoplasty data Early Q1 Phase 2 program in nerve block initiated Initiated TKA study (local administration) End-of-Phase 2 CINVANTI (HTX-019) for CINV Q1 (Jan.) NDA submission Q4 NDA Approval SUSTOL for CINV 2017 net sales guidance: $15M - $25M Initiation of Phase 3 studies NDA filing
53 Financial Summary Summary Statement of Operations (In thousands, except per share data) Year Ended December 31, 2016 Net product sales $ 1,279 Operating expenses 1 172,194 Other expenses, net (2,228) Net loss $ (173,143) Net loss per share 2 $ (4.56) Condensed Balance Sheet Data (In thousands) December 31, 2016 Cash, cash equivalents and short-term investments 3 $ 51,138 Total assets $ 67,482 Promissory note payable $ 50,000 Total stockholders deficit ($ 21,251) 1 Includes $26.0 million of non-cash, stock-based compensation expense. 2 Based on 37.9 million weighted average common shares outstanding for the year ended December 31, In January 2017, we completed an underwritten public offering of our common stock for net proceeds of $163.7 million. As of December 31, 2016, our pro-forma cash, cash equivalents and short-term investments and pro-forma shares outstanding, adjusting for the January 2017 public offering, was $214.8 million and 53.5 million, respectively.
Company Update F e b r u a r y
Company Update February 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. August 2017
Company Update August 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that
More informationCompany Update. October 12, 2017
Company Update October 12, 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationHTX-011 Postoperative Pain Program Topline Results From Phase 3. March 19, 2018
HTX-011 Postoperative Pain Program Topline Results From Phase 3 March 19, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation
More informationCompany Update. September 2016
Company Update September 2016 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. August 8, 2018
Company Update August 8, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. June 24, 2018
Company Update June 24, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. November 2015
Company Update November 2015 Legal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements
More informationCompany Update N o v e m b e r
Company Update November 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationHTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018
HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies June 21, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities
More informationCompany Update. M ARCH 27 th, 2018
Company Update M ARCH 27 th, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. JP Morgan Conference January 2018
Company Update JP Morgan Conference January 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We
More informationCompany Update. JUNE 5 th, 2018
Company Update JUNE 5 th, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCompany Update. March 2018
Company Update March 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that
More informationCorporate Presentation
Corporate Presentation Improving the Lives of Patients by Developing Best-in-Class Medicines that Address Unmet Medical Needs NASDAQ: HRTX August 2015 Forward-Looking Statements This presentation contains
More informationCompany Update. M arch 2018
Company Update M arch 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that
More informationCompany Update. February 2018
Company Update February 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationCorporate Update. November 27, 2018
Corporate Update November 27, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationis to improve the lives of patients by developing novel, best-in-class treatments
OUR MISSION is to improve the lives of patients by developing novel, best-in-class treatments to address some of the most important unmet patient needs. OUR MISSION We aim to develop patient-focused solutions
More informationHTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy
HTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy Eugene Viscusi, 1 Oscar DeLeon-Casasola, 2 TJ Gan,
More informationCorporate Update. January 7, 2019
Corporate Update January 7, 2019 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationI.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results
I.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of I.V. CR845
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationFinancing Overhang Removed, HTX-011 Delivering Consistently, CINV Franchise Materializing: Initiating BUY/$28 TP
Heron Therapeutics, Inc February 7, 2017 BUY (HRTX, $13.35) Financing Overhang Removed, HTX-011 Delivering Consistently, CINV Franchise Materializing: Initiating BUY/$28 TP Jonathan Aschoff, Ph.D. 212.417.8277
More informationXARACOLL Phase 3 Results Webcast. MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016
XARACOLL Phase 3 Results Webcast MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016 Forward Looking Statements This presentation contains forward-looking statements about our ongoing development of XARACOLL
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationForward Looking Statements
September 2015 Forward Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to future financial results including AcelRx s plans to
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationInnovative Approaches and New Technology to Gain Access
Innovative Approaches and New Technology to Gain Access The following is intended only for presentation to the Reimbursement and Access 2017 audience, August 17, 2017. This information is not for promotional
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationFlexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
May 8, 2018 Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights Company booked net ZILRETTA sales of $2.2 million in Q1 Positive developments in Medicare reimbursement
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationSoliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018
Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationEfficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery. Pamela P.
Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery Pamela P. Palmer, MD, PhD Disclosures for Dr. Pamela Palmer AcelRx employee Currently own
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationSufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type
Sufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type 2016 European Society of Regional Anesthesia Congress Maastricht,
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationMarket Potential for MDX Alcobra Investor Breakfast July 15, 2014
Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,
More informationPhase 3c Topline Results. Page 1
Phase 3c Topline Results Page 1 Important Information Any statements in this presentation about future expectations, plans and prospects for the Company including the development and regulatory status
More informationLJPC-401 Phase 1 Results and Development Update. September 7, 2016
LJPC-401 Phase 1 Results and Development Update September 7, 2016 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationBioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of
BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of For adult patients with PKU who have uncontrolled blood phenylalanine (Phe) concentrations > 600 µmol/l on existing management May 24,
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationTargeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationGIAPREZA (angiotensin II) Update
Corporate Presentation GIAPREZA (angiotensin II) Update NASDAQ: LJPC December 2017 0 Forward Looking Statement These slides contain forward-looking statements as that term is defined in the Private Securities
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Worldwide net Ocaliva (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationMonogram Announces 2008 Second Quarter Financial Results
Monogram Announces 2008 Second Quarter Financial Results 66% Revenue Growth; HERmark Breast Cancer Assay launched commercially - Conference call today at 4:30 p.m. ET - SOUTH SAN FRANCISCO, Calif., July
More informationBDSI Corporate Overview
BDSI Corporate Overview June 2017 1 2017 BioDelivery Sciences International Inc. All Rights Reserved. Jefferies 2017 Healthcare Conference Dr. Mark A. Sirgo President and Chief Executive Officer June 6
More informationLJPC-501 Market Opportunity
LJPC-501 Market Opportunity NASDAQ: LJPC July 2015 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPrucalopride (SHP555) Update for Global Investors
Prucalopride (SHP555) Update for Global Investors March 7, 2018 Prucalopride - Introduction U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation (CIC) Prucalopride
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationNerve Blocks & Long Acting Analgesia for Plastic Surgeons. Karol A Gutowski, MD, FACS
Nerve Blocks & Long Acting Analgesia for Plastic Surgeons Karol A Gutowski, MD, FACS Disclosures None related to this topic Why is Non-Opioid Analgesia Important Opioid epidemic Less opioid use Less PONV
More informationBroad and clinically important benefits beyond the initial registrational endpoints are now reported.
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom
More information